Investors Shareholders

About
Teams
Sustainability
Investments
Media

Important notice

Current portfolio

Eloxx Pharma

Developing Therapeutics to treat genetic diseases

Sector
Healthcare
Country
United States
Fund
LSP 5
Entry
2017
Web
eloxxpharma.com

Sector
Healthcare
Country
United States
Fund
LSP 5
Entry
2017
Web
eloxxpharma.com

Eloxx Pharma

Latest news

25 July 2024
EQT to sell its stake in fiber-to-the-home network Fiberklaar
18 July 2024
EQT AB (publ) Half-year Report 2024
16 July 2024
EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
12 July 2024
Introducing ThinQ by EQT
10 July 2024
EQT AB assigned ‘A-’ (Stable) credit rating by S&P

0

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news

Regulatory News

EQT News

Preferred languageEnglishSwedish

Email address

Offices

Europe
North America
- New York
- San Francisco
APAC

About

EQT Playbook
Fund investors
Purpose and Culture
EQT Foundation
- EQT Foundation
Careers
- Life at EQT
- EQT Academy
Motherbrain

Teams

Roles

Sustainability

Future-proofing

Business Segments

Private Capital
Real Assets

Investments

Portfolio

Shareholders

About EQT AB Group
IPO on Nasdaq Stockholm
Reports and Presentations
Corporate Governance
About the Share

Media

Newsroom
- News
- Reports and presentations

Contact

Media
- Press Contact
Follow

Legal

Sustainable Finance Disclosure
Complaints Handling Procedure
Glossary and Definitions
Policies
Cookie Policy
Terms and Conditions

About

Teams

Sustainability

Investments

Shareholders

Media

Contact

Legal

A purpose-driven global investment organization

© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180